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Abstract
Introduction: Prospective studies have consistently suggested that nut consumption is inversely related to fatal and non-
fatal coronary heart disease. Limited data are available on the epidemiological associations between nut intake and
cardiometabolic risk factors.
Objective: To evaluate associations between frequency of nut consumption and prevalence of cardiometabolic risk factors
[obesity, metabolic syndrome (MetS), type-2 diabetes, hypertension, and dyslipidemia] in a Mediterranean population at
high cardiovascular risk.
Materials and Methods: Cross-sectional study of 7,210 men and women (mean age, 67 y) recruited into the PREDIMED
study. MetS was defined by the harmonized ATPIII and IDF criteria. Diabetes and hypertension were assessed by clinical
diagnosis and dyslipidemia (high triglycerides, low HDL-cholesterol, and hypercholesterolemia) by lipid analyses. Nut
consumption was assessed using a validated food frequency questionnaire and categorized as ,1, 1–3, and .3 servings/
wk. Control of confounding was done with multivariate logistic regression.
Results: Compared to participants consuming ,1 serving/wk of nuts, those consuming .3 servings/wk had lower adjusted
odds ratios (OR) for obesity (0.61, 95% confidence interval 0.54 to 0.68; P-trend ,0.001), MetS (0.74, 0.65 to 0.85; P-
trend,0.001), and diabetes (0.87, 0.78 to 0.99; P-trend = 0.043). Higher nut consumption was also associated with lower risk
of the abdominal obesity MetS criterion (OR 0.68, 0.60 to 0.79; P-trend,0.001). No significant associations were observed for
the MetS components high blood pressure, dyslipidemia, or elevated fasting glucose.
Conclusions: Nut consumption was inversely associated with the prevalence of general obesity, central obesity, MetS, and
diabetes in subjects at high cardiovascular risk.
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Introduction
The worldwide prevalence of obesity, the metabolic syndrome
(MetS), and associated comorbidities with a high risk of disability
and death, such as type-2 diabetes, hypertension and cardiovas-
cular disease (CVD), is steadily increasing and has become a major
public health problem. The MetS, composed of abdominal obesity
associated with insulin resistance, fasting hyperglycemia or frank
diabetes, high triglycerides, low HDL-cholesterol (HDL-C), and
high blood pressure, is a paradigm of increased risk for CVD [1].
MetS roughly affects one out of each three adults in the world
population [2], but this is a conservative estimate based on the
rather high waist circumference thresholds of the National
Cholesterol Education Program Adult Treatment Panel III
definition [1] and would certainly be higher if recently defined
ethnic-specific cutoffs for abdominal obesity were used [3].
With the rapidly rising prevalence of MetS and diabetes, there is
an urgent need to identify preventive lifestyle strategies. As
recently reviewed [4], landmark clinical trials of lifestyle changes in
overweight or obesity subjects with prediabetes, most of whom had
MetS, have shown that diet and exercise leading to weight loss
consistently reduce cardiometabolic risk factors and the incidence
of diabetes. There is also epidemiological and clinical trial
evidence supporting that increased adherence to the Mediterra-
nean diet (MedDiet) [5] and consumption of foods rich in
antioxidants, n-3 fatty acids, or minerals other than sodium [6]
relates to a reduced prevalence of the MetS.
Based on their nutrient profile and known effects on heart
health [7], nuts are a unique food that could be useful to improve
cardiometabolic risk factors, the MetS and diabetes. Nuts are
already considered as a key component of a cardioprotective diet
[8]. In fact, nuts were the first whole food that was granted a heart
health claim by the US Food and Drug Administration [9]. Nuts
are a rich source of energy because 45 to 75% of their weight is
made up of fat, but this fat is mostly unsaturated [10]. Nuts also
contain high-quality protein, fiber, antioxidant vitamins, and
minerals such as magnesium, copper, selenium, potassium, and
little sodium except when salted [11,12]. Other bioactive
compounds that abound in nuts are phytosterols [12] and
polyphenols, particularly flavanoids and proanthocyanidins
[13,14].
While prospective studies have shown a consistent association
between increased nut consumption and a reduced risk of
coronary heart disease [7], the epidemiological evidence for a
beneficial effect on weight gain or obesity [15], the risk of MetS
and diabetes [16], or hypertension incidence [17] is less clear.
Also, clinical trials with different types of nuts, including peanuts
(technically a legume, but included in the nut group because of a
similar nutrient profile), have consistently demonstrated that
regular consumption has a hypocholesterolemic effect [7,18].
There is also suggestive evidence that nut consumption improves
oxidation [19], inflammation [20], and endothelial function [17],
while no clear effect on blood pressure has been detected thus far.
On the other hand, data on nut consumption and glycemic control
or insulin sensitivity are inconclusive [16].
Given these uncertainties, it is important to assess associations
between nut consumption and cardiometabolic risk factors in a
large sample of individuals with a wide range of nut intake. Such is
the cohort of participants in the PREDIMED study, a large
multicenter dietary intervention trial for the primary prevention of
CVD [21]. Therefore, in a cross-sectional assessment, we
examined the associations between frequency of nut intake and
prevalence of cardiovascular risk factors in subjects at high
cardiovascular risk recruited into the PREDIMED trial.
Materials and Methods
Study Population
This cross-sectional analysis was conducted with the baseline
data of participants in the PREDIMED study (PREvencio´n con
DIeta MEDiterra´nea), a large, parallel-group, multicenter,
randomized, controlled clinical trial aimed to assess the effects of
the MedDiet on the primary prevention of CVD (www.predimed.
es and www.predimed.org). The design of the PREDIMED trial
has been reported in detail elsewhere [21]. A total of 7,447
participants, aged between 55–80 y in men and 60–80 y in women
were recruited between October 2003 and January 2009. Eligible
participants were free of CVD at baseline, and had either type-2
diabetes or at least 3 of the following cardiovascular risk factors:
current smoking, body mass index (BMI) $25 kg/m2; blood
pressure $140/90 mmHg or treatment with antihypertensive
medication; serum LDL-cholesterol (LDL-C) $160 mg/dL or
treatment with lipid-lowering drugs; HDL-cholesterol (HDL-C)
#40 mg/dL in men and #50 mg/dL in women; or family history
of early-onset CVD (#55 years in men and #60 years in women).
Exclusion criteria included any severe chronic illness, alcohol or
drug abuse, and BMI $40 kg/m2. The local institutional review
boards approved the protocol and all participants provided written
informed consent.
Nut Consumption
In the present study peanuts, almonds, hazelnuts, walnuts, pine
nuts, pistachios, macadamia and cashews were all considered nuts.
A 137-item food frequency questionnaire (FFQ) was used to
determine food consumption. Detailed information about the
development of the FFQ and its reproducibility and validity in the
PREDIMED cohort has been previously reported [22]. Twenty
eight grams of nuts was considered one serving.
Adherence to the Mediterranean Diet
To assess adherence to the MedDiet, a 14-item questionnaire
with a value of 0 or 1 for each dietary component was used [21].
Each item refers to a characteristic feature of the MedDiet, for
example: amount and use of olive oil for cooking and dressing;
weekly intake of nuts; increased consumption of vegetables, fruits,
legumes and fish; recommended intake of white meat instead of
red or processed red meat, moderate wine consumption; avoid
eating butter, fast-food, sweets, pastries or sugar-sweetened
beverages; to dress dishes by typical ‘‘sofrito’’ sauce (using tomato,
garlic, onion and spices with olive oil). For the purpose of
controlling potential confounding by the overall dietary pattern we
used this score as a covariate in multivariable models. Therefore,
in this study the question on nut consumption was removed and
only a 13-point score was considered (minimum score = 0,
maximum score = 13).
Metabolic Syndrome
MetS was defined according to the updated joint criteria of the
International Diabetes Federation (IDF) and the American Heart
Association/National Heart, Lung, and Blood Institute [3].
Participants received a diagnosis of MetS if they presented at
least 3 of the followings 5 components: 1) elevated waist
circumference ($102 cm for men and $88 cm for women); 2)
elevated serum triglycerides ($150 mg/dL) or triglyceride-lower-
ing medication use; 3) reduced HDL-C (,40 mg/dL in men and
,50 mg/dL in women); 4) elevated blood pressure ($130/85 mm
Hg) or use of antihypertensive medication; and 5) high fasting
glucose ($100 mg/dL) or hypoglycaemic drug treatment.
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Assessment of Other Outcomes
Obesity was defined as BMI $30 kg/m2. Diabetes and
hypertension were considered to be present by clinical diagnosis
and/or use of antidiabetic or antihypertensive medication,
respectively. Atherogenic dyslipidemia was defined by the
association of serum triglycerides $150 mg/dL and HDL-C
,40 mg/dL in men or ,50 mg/dL in women. Hypercholester-
olemia was considered when LDL-C was $130 mg/dL.
Procedures
We administered a general questionnaire about lifestyle,
including smoking habits, socio-demographics conditions, and
history of illnesses and medication use. A validated Spanish version
of the Minnesota Leisure Time Physical Activity Questionnaire
was also administered. Trained personnel measured weight (kg)
and height (cm) with calibrated scales and a wall-mounted
stadiometer, respectively, and waist circumference with an
anthropometric tape midway between the lower rib and the
superior border of the iliac crest. BMI was calculated as weight in
kilograms divided by the square of height in meters. Blood
pressure was measured in triplicate with 5-min intervals between
each measurement with the subject in a sitting position by using a
validated semiautomatic oscillometer (Omron HEM-705CP,
Hoofddorp, The Netherlands). After an overnight fast, samples
of serum, EDTA plasma and urine were obtained and stored at
280uC until analysis. Serum glucose, triglycerides and cholesterol
concentrations were determined by standard enzymatic methods
in automatic autoanalyzers.
Statistical Analyses
Results are expressed as mean 6 SD or percentages. We
divided participants into three categories of nut consumption at
baseline (less than one serving/wk, 1–3 servings/wk, and more
than 3 servings/wk). Participants with extremes of total energy
intakes (,500 or .3500 kcal/day in women, and ,400 or
.4000 kcal/day in men) were excluded. We also excluded
participants reporting nut intake greater than 100 g/d.
Table 1. General characteristics of the study population by servings/week of nuts.
Nut consumption
,1 serving/week
(n = 2796)
1–3 servings/week
(n = 2125)
.3 servings/week
(n = 2289) P value1
Nut intake (g/day) 0.4860.86 5.8861.82 25.48613.23
Age (years) 67.466.3 66.666.2 67.066.2 ,0.001
Women, % (n) 62.2 (1740) 56.0 (1189) 53.0 (1214) ,0.001
BMI (kg/m2) 30.464.0 29.963.8 29.463.7 ,0.001
Weight (kg) 77.2612.0 77.2612.2 75.9611.6 ,0.001
Waist circumference (cm) 101.2610.5 100.9610.4 99.2610.0 ,0.001
Leisure-time energy expenditure
in physical activity (MET-min/day)
201.26218.5 234.26238.4 264.16257.2 ,0.001
Smoking status, % (n) ,0.001
Never 63.6 (1779) 61.0 (1296) 59.4 (1360)
Current 14.7 (411) 14.2 (301) 12.7 (291)
Former 21.7 (606) 24.8 (528) 27.9 (638)
Marital status (% married) (n) 72.9 (2035) 78.1 (1658) 78.8 (1804) ,0.001
Education level, % (n) ,0.001
Illiterate/primary education 81.6 (2281) 74.8 (1590) 75.6 (1730)
Secondary education 13.1 (366) 16.5 (351) 16.2 (377)
Academic/graduate 5.3 (149) 8.7 (184) 8.0 (182)
Mediterranean diet adherence (13-point score) 8.1 (1.8) 8.3 (1.8) 8.6 (1.8) ,0.001
Obesity (BMI $30 kg/m2), % (n) 53.1 (1486) 46.4 (987) 39.1 (895) ,0.001
Diabetes, % (n) 51.4 (1438) 47.6 (1011) 46.2 (1057) ,0.001
Hypertension, % (n)2 83.9 (2346) 81.7 (1737) 82.3 (1883) 0.108
Hypercholesterolemia (LDL-C .130 mg/dl), % (n) 47.7 (1201) 49.3 (964) 48.9 (1035) 0.528
Medication use, % (n)
Oral antidiabetic drugs 34.7 (968) 31.8 (676) 29.7 (678) ,0.001
Insulin 8.9 (247) 6.0 (128) 5.3 (120) ,0.001
Antihypertensive drugs 75.6 (2108) 71.4 (1516) 71.1 (1621) 0.001
Statins 40.8 (1141) 39.8 (846) 39.8 (912) 0.710
Fibrates 3.5 (97) 4.1 (88) 4.2 (96) 0.326
Data are mean 6 SD. Abbreviations: BMI: body mass index, LDL-C: low-density lipoproteins cholesterol.
1ANOVA or chi-square test as appropriate.
2Defined by medical diagnosis.
doi:10.1371/journal.pone.0057367.t001
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To compare quantitative and categorical variables between
categories of nut consumption, ANOVA and chi-square tests were
used, respectively. We used multiple logistic regression models to
examine the associations of the prevalence of different outcomes
across categories of nut consumption. Results are expressed as
odds ratios (OR) and 95% confidence intervals (CI). Regressions
models were adjusted for potential confounding factors using three
different models to allow for different levels of adjustment. The
first model was adjusted for age, sex, geographic recruitment area
and BMI (kg/m2); the second model was additionally adjusted for
smoking status (no smoker, former and current), leisure time
physical activity (MET-min/day), and education level (primary or
illiterate, secondary and university); the third model was addition-
ally adjusted for energy consumption (kcal/d) and adherence to
the Mediterranean diet (13-point score). Obesity, abdominal
obesity and metabolic syndrome were not adjusted for BMI
because of collinearity among these variables. Hypercholesterol-
emia was additionally adjusted by statin treatment (yes/no).
Analyses were performed by using the SPSS statistical package
version 19.0 (SPSS Inc., Chicago, IL) and the level of significance
was set at p,0.05.
Results
After excluding participants with total energy intake out of
predefined limits (n = 153) or implausible values for nut consump-
tion (n = 6), 7,210 participants remained for the present analysis.
There were a total of 3,067 men and 4,143 women with mean age
67 y. Average nut consumption in each of the 3 categories was
0.4860.86, 5.8861.82 and 25.48613.23 g/d, respectively. The
general characteristics of participants are summarized in Table 1.
Compared to individuals consuming less than one serving of nuts
per wk, those consuming more than 3 servings per wk were
younger and more physically active and had a lower BMI and
waist circumference, and a higher adherence to the MedDiet. In
addition the percentage of current smokers was lower and the
prevalence of individuals with high education level was higher in
the highest category of nut consumption. A lower percentage of
subjects in this category were obese or had diabetes. Table 2
shows similar data for MetS, its components, and atherogenic
dyslipidemia. The prevalence of MetS, abdominal obesity, and
atherogenic dyslipidemia decreased across categories of nut intake,
while participants consuming .3 servings/wk showed a lower
prevalence of high triglycerides, low HDL-C, and high fasting
glucose compared with those consuming ,1 serving/wk. On the
other hand, the prevalence of hypertension was unrelated to
frequency of nut consumption.
Table 3 shows the multivariable-adjusted ORs for the main
outcomes by categories of nut consumption. In fully-adjusted
models, participants in the upper category of nut consumption had
a lower prevalence of obesity (OR = 0.61, 95% CI 0.54 to 0.68; P-
trend ,0.001), diabetes (OR = 0.87, 0.78 to 0.99; P-trend = 0.043)
and MetS (OR = 0.74, 0.65 to 0.85; P-trend ,0.001) compared
with those in the lowest category. No associations were detected
for hypertension, atherogenic dyslipidemia, or hypercholesterol-
emia. Table 4 depicts adjusted ORs for MetS components of
individuals consuming .3 servings of nuts per week versus those
with infrequent nut consumption. As shown, high nut consumers
had a lower risk of abdominal obesity (OR = 0.68, 0.60 to 0.79; P-
trend,0.001) compared to infrequent consumers of nuts. No
associations were shown for high fasting glucose, high blood
pressure, high triglycerides, or low HDL-C.
Supplementary Tables S1 and S2 show the ORs of each of the
confounders used in the multivariate regression analyses in
Tables 3 and 4 for the same cardiometabolic risk factors.
Discussion
In this cross-sectional study conducted in elderly subjects at high
cardiovascular risk living in a Mediterranean country, a high
frequency of nut consumption was inversely associated with the
prevalence of obesity, MetS and diabetes, suggesting that nut
consumption has protective effects on cardiometabolic risk. The
suggested benefit on MetS was ascribable to a reduced frequency
of abdominal obesity, but not of high fasting glucose, hypertension
or atherogenic dyslipidemia. These findings may explain in part
the decreased risk of CVD mortality shown for frequent nut
consumers in prospective studies [7].
The observed inverse association between frequency of nut
consumption and prevalence of obesity might seem counterintu-
itive, since nuts are high-fat, energy-dense foods. However, our
results concur not only with previous cross-sectional studies, but
also with large prospective cohorts with sufficiently long follow-up
showing an inverse association between frequency of nut
consumption and BMI or risk of obesity [15,23–25]. They are
also in accordance with the results of short and medium-term
Table 2. Prevalence of metabolic syndrome, its components, and atherogenic dyslipidemia by servings/week of nuts.
Nut consumption
,1 serving/week
(n = 2796)
1–3 servings/week
(n = 2125)
.3 servings/week
(n = 2289) P value1
Metabolic syndrome, % (n) 69.7 (1770) 64.3 (1266) 59.9 (1251) ,0.001
Abdominal obesity, % (n) 77.6 (2089) 74.4 (1546) 66.7 (1487) ,0.001
Hypertriglyceridemia, % (n) 33.1 (842) 29.5 (578) 30.0 (635) 0.014
Low HDL-cholesterol, % (n) 33.2 (841) 31.2 (613) 28.3 (602) 0.001
High blood pressure, % (n)2 94.3 (2625) 93.7 (1984) 94.7 (2155) 0.356
Fasting plasma glucose
$100 mg/dL, % (n)
69.7 (1784) 64.1 (1267) 65.8 (1365) ,0.001
Atherogenic dyslipidemia, % (n)3 14.9 (378) 12.5 (244) 11.5 (245) 0.002
1Chi-square test.
2Defined as blood pressure $130/85 mmHg or antihypertensive drug treatment.
3Defined as serum triglycerides $150 mg/dL associated with HDL-cholesterol ,40 mg/dL in men or ,50 mg/dL in women.
doi:10.1371/journal.pone.0057367.t002
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controlled feeding trials showing that nut supplementation of usual
diets does not induce weight gain in spite of the expected increase
in energy intake, as recently reviewed [7]. Other clinical trials have
suggested that nuts may favor weight loss within energy-restricted
diets, possibly by increasing compliance, but enhanced satiety,
increased thermogenesis [26], incomplete mastication and fat
malabsorption, documented as increased fecal fat excretion in
several nut studies [27], could also be contributing factors.
Few studies have examined the association between nut
consumption and MetS. In our study the frequency of nut
consumption was inversely associated with MetS and with the
central obesity component of the MetS. Similar findings were
recently reported in the NHANES 1999–2004 cohort, wherein
increased nut consumption related to a decreased prevalence of
selected CVD risk factors and MetS [28]. In a recent study,
including 9987 participants of the SUN cohort followed for 6
years, participants who consumed $2 servings of nuts per week
Table 3. Multivariable-adjusted odds ratios (95% confidence intervals) for the prevalence of metabolic risk factors by category of
nut consumption.
Nut consumption
,1 serving/week
(n = 2796)
1–3 servings/week
(n = 2125)
.3 servings/week
(n = 2289) P for trend
Obesity (BMI.= 30 kg/m2); n = 7210
Unadjusted model 1 (ref.) 0.76 (0.68–0.86) 0.57 (0.51–0.63) ,0.001
Model 1 1 (ref.) 0.78 (0.70–0.88) 0.58 (0.52–0.65) ,0.001
Model 2 1 (ref.) 0.80 (0.72–0.90) 0.61 (0.54–0.68) ,0.001
Model 3 1 (ref.) 0.80 (0.71–0.90) 0.61 (0.54–0.68) ,0.001
Diabetes mellitus; n = 7210
Unadjusted model 1 (ref.) 0.86 (0.77–0.96) 0.81 (0.73–0.91) 0.001
Model 1 1 (ref.) 0.85 (0.76–0.96) 0.78 (0.69–0.87) ,0.001
Model 2 1 (ref.) 0.86 (0.76–0.96) 0.77 (0.69–0.86) ,0.001
Model 3 1 (ref.) 0.91 (0.81–1.02) 0.87 (0.78–0.99) 0.043
Hypertension; n = 7209
Unadjusted model 1 (ref.) 0.86 (0.74–1.00) 0.89 (0.77–1.03) 0.251
Model 1 1 (ref.) 0.93 (0.80–1.08) 1.02 (0.88–1.19) 0.580
Model 2 1 (ref.) 0.91 (0.78–1.06) 1.00 (0.86–1.16) 0.764
Model 3 1 (ref.) 0.91 (0.78–1.07) 1.01 (0.87–1.19) 0.602
Atherogenic dislypidemia1; n = 6602
Unadjusted model 1 (ref.) 0.81 (0.68–0.96) 0.74 (0.62–0.88) 0.002
Model 1 1 (ref.) 0.84 (0.71–1.00) 0.81 (0.68–0.96) 0.032
Model 2 1 (ref.) 0.85 (0.71–1.01) 0.84 (0.70–0.99) 0.083
Model 3 1 (ref.) 0.88 (0.74–1.05) 0.89 (0.74–1.07) 0.327
Hypercholesterolemia (LDL-C .130 mg/dl); n = 6587
Unadjusted model 1 (ref.) 1.07 (0.95–1.20) 1.05 (0.94–1.18) 0.527
Model 1 1 (ref.) 1.07 (0.95–1.20) 1.06 (0.941.20) 0.396
Model 2 1 (ref.) 1.07 (0.95–1.20) 1.06 (0.94–1.20) 0.418
Model 3 1 (ref.) 1.05 (0.93–1.18) 1.02 (0.90–1.16) 0.857
Metabolic syndrome2; (n = 6409)
Unadjusted model 1 (ref.) 0.79 (0.69–0.89) 0.63 (0.56–0.72) ,0.001
Model 1 1 (ref.) 0.81 (0.72–0.93) 0.65 (0.58–0.74) ,0.001
Model 2 1 (ref.) 0.84 (0.74–0.95) 0.68 (0.60–0.78) ,0.001
Model 3 1 (ref.) 0.87 (0.76–0.99) 0.74 (0.65–0.85) ,0.001
Abbreviations: LDL-C: low-density lipoproteins cholesterol: BMI: body mass index (kg/m2).
1Defined as serum triglycerides $150 mg/dL associated with HDL-cholesterol ,40 mg/dL in men or ,50 mg/dL in women.
2Metabolic syndrome and obesity were not adjusted by BMI.
Multiple logistic regression was used to assess the association between frequency of nut intake and cardiovascular risk factors.
Multiple logistic regression taking into an account the median of each category of nut consumption was used to generate the P for linear trend.
Model 1 was adjusted for: age (years), sex, geographic recruitment area and BMI (kg/m2).
Model 2 was additionally adjusted for smoking status (never, former or current smoker), leisure time physical activity (MET-min/day) and education level (primary or
illiterate, secondary and university).
Model 3 was additionally adjusted for energy intake (kcal/day) and adherence to the Mediterranean diet (13-point score). In case of hypercholesterolemia this model
was additionally adjusted by treatment with statins.
Extremes of total energy intake were excluded.
doi:10.1371/journal.pone.0057367.t003
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had a 32% lower risk of developing MetS than those who never/
almost never consumed nuts, and the association appeared to be
stronger among women [29]. In addition, 1-y results from a
subsample of the first 1224 participants of the PREDIMED
randomized trial showed that a Mediterranean diet supplemented
with nuts decreased MetS prevalence, mainly by reversing
abdominal obesity [30]. Now we include all the participants in
the trial in this baseline cross-sectional assessment. In the present
study we found no association between nut consumption and the
hyperglycemia component of the MetS. An earlier report of the
PREDIMED trial with 772 participants and a 3-month follow-up
[31] showed that the MedDiet enriched with nuts was associated
with improved fasting glucose concentrations. Another cross-
sectional assessment in the first 3204 participants supported an
inverse association between adherence to the MedDiet and
metabolic risk factors (diabetes, obesity and hypertension) [32].
This is the reason why we controlled for overall adherence to the
MedDiet using the 13-point score. However the effects of nut
consumption on insulin resistance and glycemic control are
controversial, especially in individuals with MetS [33–36].
In our study subjects who consumed .3 servings of nuts/wk
had a 22% lower prevalence of a diagnosis of diabetes than those
consuming ,1 serving/wk. As reviewed [16], prior epidemiolog-
ical evidence on the effects of nuts on diabetes risk was
inconclusive. Four large prospective studies have evaluated the
association between the frequency of nut consumption and the risk
of diabetes, the Nurses’ Health Study [37], the Iowa Women’s
Health Study [38], the Shanghai Women’s Health Study [39], all
carried out in women, and the Physicians’ Health Study,
conducted in a cohort of men [40]. After adjustment for
confounders, nut consumption was inversely associated with
diabetes risk in two studies [37,39], while no association was
found in the other two studies [38,40]. Several factors may
influence the effect of nuts on the pathophysiological process of
diabetes. Nuts are rich in unsaturated fatty acids, fiber, magne-
sium, and other antioxidant and phytochemical constituents with
potential beneficial effects on insulin sensitivity and inflammation.
Table 4. Odds ratios (ORs) and 95% confidence intervals (CIs) for components of metabolic syndrome by category of nut
consumption.
Nut consumption
,1 serving/week
(n = 2796)
1–3 servings/week
(n = 2125)
.3 servings/week
(n = 2289) P for trend
Abdominal obesity; n = 6999
Unadjusted model 1 (ref.) 0.84 (0.73–0.96) 0.58 (0.51–0.65) ,0.001
Model 1 1 (ref.) 0.87 (0.76–0.99) 0.58 (0.51–0.66) ,0.001
Model 2 1 (ref.) 0.92 (0.80–1.06) 0.64 (0.56–0.72) ,0.001
Model 3 1 (ref.) 0.96 (0.83-1.10) 0.68 (0.60–0.79) ,0.001
Hypertriglyceridemia; n = 6611
Unadjusted model 1 (ref.) 0.84 (0.74–0.96) 0.87 (0.76–0.98) 0.067
Model 1 1 (ref.) 0.84 (0.74–0.96) 0.90 (0.79–1.02) 0.216
Model 2 1 (ref.) 0.86 (0.75–0.97) 0.92 (0.81–1.05) 0.427
Model 3 1 (ref.) 0.87 (0.76–0.99) 0.96 (0.84–1.09) 0.862
Reduced HDL-C; n = 6617
Unadjusted model 1 (ref.) 0.92 (0.81–1.04) 0.80 (0.70–0.90) ,0.001
Model 1 1 (ref.) 0.94 (0.82–1.06) 0.86 (0.75–0.97) 0.018
Model 2 1 (ref.) 0.97 (0.85–1.10) 0.90 (0.79–1.03) 0.121
Model 3 1 (ref.) 1.00 (0.88–1.14) 0.98 (0.86–1.12) 0.740
Elevated blood pressure; n = 6585
Unadjusted model 1 (ref.) 0.92 (0.69–1.24) 1.01 (0.75–1.36) 0.843
Model 1 1 (ref.) 1.00 (0.74–1.34) 1.17 (0.87–1.58) 0.259
Model 2 1 (ref.) 0.96 (0.71–1.29) 1.13 (0.83–1.53) 0.368
Model 3 1 (ref.) 0.96 (0.71–1.29) 1.12 (0.81–1.53) 0.411
Elevated fasting glucose; n = 6539
Unadjusted model 1 (ref.) 0.79 (0.69–0.89) 0.84 (0.74–0.95) 0.047
Model 1 1 (ref.) 0.80 (0.70–0.91) 0.84 (0.74–0.95) 0.034
Model 2 1 (ref.) 0.80 (0.70–0.91) 0.83 (0.73–0.94) 0.024
Model 3 1 (ref.) 0.85 (0.74–0.96) 0.95 (0.83–1.08) 0.845
Model 1 was adjusted for: age (years), sex, geographic recruitment area and BMI (kg/m2). The abdominal obesity component of the metabolic syndrome was not
adjusted by BMI.
Model 2 was additionally adjusted for smoking status (never, former or current smoker), leisure time physical activity (MET-min/day) and education level (primary or
illiterate, secondary and university).
Model 3 was additionally adjusted for energy intake (kcal/day) and adherence to the Mediterranean diet (13-point score).
Extremes of total energy intake were excluded.
doi:10.1371/journal.pone.0057367.t004
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In fact, several clinical trials suggest that nuts can modulate
oxidative stress [19], inflammation [20], endothelial function [17],
and insulin resistance [16,41]. Recently, nut supplementation has
been demonstrated to ameliorate glycemic control in patients with
diabetes [42]. Still, reverse causation due to a reduced consump-
tion of fat-rich nuts by diabetic patents on advice of their
caregivers is an alternate explanation for the observed inverse
association between nut consumption and prevalence of diabetes.
We found no association of nut consumption with clinical
hypertension or high blood pressure as MetS component. Prior
studies showed conflicting results. Only two prospective studies
have evaluated the association between nut consumption and
incident hypertension [40,43]. In a prospective cohort from the
Physicians’ Health Study I, Djousse´ et al. [40] reported a lower
incidence of hypertension in usual consumers of nuts compared to
non consumers. However, this association was mainly observed
among lean subjects (BMI ,25 kg/m2) and not in overweight or
obese individuals. These results must be taken with caution,
however, because salt intake and changes in weight, two major
factors that influence the risk of hypertension, were not accounted
for in this study. The second study, which involved Spanish
university graduates followed for a median of 4.3 years in the SUN
cohort [43], found no association between nut consumption and
incidence of hypertension after adjusting for several confounders,
including exposure to salt and weight changes during follow-up.
Also, as recently reviewed [17], few clinical trials have evaluated
the effect of nut consumption on blood pressure. Most studies have
found either a beneficial effect or no effect, but it must be noted
that ambulatory blood pressure monitoring, the best standard for
blood pressure measurements, was used in none of these studies.
The lack of association between the frequency of nut consumption
and hypertension in our study could be explained by the fact that
more than 80% of study subjects had a diagnosis of clinical
hypertension and more than 90% had high blood pressure as a
MetS component.
We observed no association between nut consumption and
triglycerides or HDL-C, the lipid components of MetS, or with the
simultaneous occurrence of high triglycerides and low HDL-C
(atherogenic dyslipidemia). The NHANES 1999–2004 study [28]
found that consumers of nuts and peanuts had a 20% lower risk of
low HDL-C, while the 3-mo report of the first 772 participants in
the PREDIMED trial [31] showed reduced triglycerides and
increased HDL-C with the nut-enriched MedDiet. However, a
recent pooled analysis of clinical studies showed that nut
consumption had no effect on HDL-C, although it reduced
triglycerides when they were elevated at baseline [18]. This report
also showed that nut intake induces a consistent, dose-related
reduction of total cholesterol and LDL-C [18], which is counter to
the lack of association between nut consumption and LDL-C in
our study. However, this might be due to the high prevalence of
obesity, a condition which appears to blunt the hypocholesterol-
emic effect of nuts [18,33].
The present study has some limitations. First, the cross-sectional
design limits the potential to discern causative relationships.
Second, the results cannot be extrapolated to the general
population because the analysis was conducted in an older
Mediterranean population at high cardiovascular risk. Third, we
adjusted the regression models for physical activity, tobacco and
adherence to the MedDiet in order to control for a wide array of
confounding factors, including lifestyle factors and potential
dietary confounders. However, we acknowledge that we cannot
discount residual confounding, namely that factors unaccounted
for in the questionnaires that imply a healthier lifestyle could
mediate the inverse association between nut consumption and
cardiometabolic risk factors. Our study also has important
strengths. Only two studies have analysed the association between
nut consumption and MetS or atherogenic dyslipidemia. The
present epidemiologic study is the first showing an association
between the frequency of nut consumption and MetS in
individuals at high cardiovascular risk. Another strength is the
large size and wide geographical origin within Spain of the
population studied.
In conclusion, in a Mediterranean population at high risk for
CVD, the frequency of nut consumption was inversely associated
with obesity, MetS, and diabetes prevalence after adjusting for
potential confounding factors. Further research is needed to
identify the mechanisms by which nuts improve cardiometabolic
risk. It also remains to be explored whether residual confounding
related to a healthier lifestyle of nut eaters might explain in part
the benefits observed in this study.
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